15. Survival results of Gemcitabine-Carboplatin regimen chemotherapy of recurrent or metastatic in triple negative breast cancer
Main Article Content
Abstract
This is a retrospective, descriptive study with longitudinal follow-up aimed at evaluating the clinical, paraclinical characteristics and survival of gemcitabine-carboplatin regimen chemotherapy of recurrent or metastatic in triple negative breast cancer at National Cancer Hospitalfrom January 2014 to December 2021. Of 52 patients enrolled in the study. The mean age was 48.7 ± 10.2 months. Mean time to first reccurence was 18,2 months. The overall response rate (ORR) of the regimen was 46.2%. The complete response rate was 9,6% and the partial response rate was 36.6%; the median progression-free survival was 6.0 ± 1.0 months (95% CI: 4.0-7.9) and median overall survival was 12.0 ± 1.8 months (95% CI: 8.5-15.5). Therefore, the regimen is highly effective, and can be widely applied in clinical practice.
Article Details
Keywords
Triple negative breast cancer, gemcitabine-carboplatin, progression-free survival
References
2. Maaren MC van, Munck L de, Strobbe LJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019; 144(2): 263-272.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007; 13(15 Pt 1): 4429-4434.
4. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010; 70(20): 7970-7980.
5. O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014; 32(34): 3840-3847.
6. A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer. Clin Breast Cancer. 2008; 8(5): 425-431.
7. Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol. 2018; 29(8): 1763-1770.
8. Zhang J, Fan M, Xie J, et al. Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. Oncotarget. 2015; 6(40): 43135-43143.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007; 13 (15 Pt 1): 4429-4434.
10. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008; 113(10): 2638-2645.
11. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26(8): 1275-1281.
12. Qiu J, Xue X, Hu C, et al. Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer. J Cancer. 2016; 7(2): 167-173.
13. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012; 118(22): 5463-5472.
14. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011; 117(8): 1602-1611.
15. Trần Quốc Thiệu. Đánh Giá Hiệu Quả Điều Trị Phác Đồ Gemcitabine - Carboplatin Trên Bệnh Nhân Ung Thư vú Tát Phát, Di Căn Tại Bệnh Viện K. 2012. Luận văn Thạc sỹ y học, Đại học Y Hà Nội.